Holen Sie sich die Stockscreener-App
17.60
6.03%
-1.13
Handel nachbörslich:
17.60
Schlusskurs vom Vortag:
$18.73
Offen:
$18.38
24-Stunden-Volumen:
440.45K
Relative Volume:
1.37
Marktkapitalisierung:
$714.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-136.98M
KGV:
-4.3781
EPS:
-4.02
Netto-Cashflow:
$-126.63M
1W Leistung:
-9.70%
1M Leistung:
-11.29%
6M Leistung:
-17.37%
1J Leistung:
-42.82%
1-Tages-Spanne:
$17.00
$18.50
1-Wochen-Bereich:
$17.00
$20.04
52-Wochen-Spanne:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Vergleichen Sie AVBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
17.60 | 759.86M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-03-20 | Eingeleitet | B. Riley Securities | Buy |
| 2025-03-10 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-20 | Eingeleitet | Citigroup | Buy |
| 2024-02-20 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
How institutional ownership impacts ArriVent BioPharma Inc. stockMarket Activity Report & Consistent Profit Trading Strategies - newser.com
Why retail investors pile into ArriVent BioPharma Inc. stock2025 Market WrapUp & AI Based Buy and Sell Signals - newser.com
Will ArriVent BioPharma Inc. stock gain from lower inflationJuly 2025 Summary & Daily Price Action Insights - newser.com
Why ArriVent BioPharma Inc. stock could benefit from AI revolution2025 Market Overview & Weekly High Potential Stock Alerts - newser.com
Analyzing ArriVent BioPharma Inc. with risk reward ratio charts2025 Market Trends & Verified Entry Point Signals - newser.com
Evaluating ArriVent BioPharma Inc. with trendline analysisJuly 2025 Momentum & Expert Curated Trade Setup Alerts - newser.com
Why ArriVent BioPharma Inc. stock is favored by pension funds2025 Risk Factors & Expert Approved Trade Ideas - newser.com
How ArriVent BioPharma Inc. stock reacts to Fed rate cuts2025 Retail Activity & Long-Term Growth Stock Strategies - newser.com
Best data tools to analyze ArriVent BioPharma Inc. stock2025 Retail Activity & Low Drawdown Investment Strategies - newser.com
Multi asset correlation models including ArriVent BioPharma Inc.Weekly Stock Summary & Safe Entry Zone Identification - newser.com
Published on: 2025-11-02 12:15:30 - newser.com
Is ArriVent BioPharma Inc. stock a defensive play in 2025Portfolio Risk Summary & Pattern Based Trade Signal System - newser.com
Real time pattern detection on ArriVent BioPharma Inc. stockMarket Sentiment Report & Entry Point Confirmation Alerts - newser.com
Moody Aldrich Partners LLC Takes $1.56 Million Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
How Bharat Gears Limited Performs During Inflation Historical OverviewCandlestick Pattern Analysis & Rapid Profit Portfolio - earlytimes.in
ArriVent BioPharma’s Phase 3 Study on Firmonertinib: A Potential Game-Changer in NSCLC Treatment - TipRanks
Momentum divergence signals in ArriVent BioPharma Inc. chartBull Run & Daily Risk Controlled Trade Plans - newser.com
What is the fair value of ArriVent BioPharma Inc. stock nowPortfolio Risk Report & Free Technical Pattern Based Buy Signals - newser.com
Is ArriVent BioPharma Inc. meeting your algorithmic filter criteriaPortfolio Performance Report & Real-Time Stock Movement Alerts - newser.com
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is ArriVent BioPharma Inc. stock in correction or buying zoneQuarterly Profit Review & Low Drawdown Momentum Trade Ideas - newser.com
Published on: 2025-10-28 03:24:22 - newser.com
Why ArriVent BioPharma Inc. stock remains a top recommendationJuly 2025 Levels & Weekly Breakout Opportunity Watchlist - fcp.pa.gov.br
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):